Now in Leamington Spa

Protect your sight. Starting today.

Valeda is the first and only FDA-authorised light therapy for dry AMD. No injections. No surgery. Just a few minutes in the chair, with Sukhi Cheema by your side.

Book a macular assessment → Is Valeda right for me?

No obligation — we check your macula first and tell you straight.

First & onlyFDA-authorised treatment for dry AMD

84%improved or maintained vision at ~2 years¹

5 minutesper session · no dilation, no injections

Sukhi Eye Spa patients and clinician with the Valeda Light Delivery System

The Valeda Light Delivery System in use — the treatment you'll receive at Sukhi Eye Spa. Image: Valeda / LumiThera product literature.

Living with dry AMD

Don't just watch it happen.

Dry AMD is the leading cause of central vision loss in later life. Reading, faces, fine detail — all affected, while side vision stays sharp. For years, the only advice was to wait. Now there's more you can do.

Drusen build-up

Tiny deposits form under the retina as cells lose the energy to clear waste away.

Central blur

Reading, faces and fine detail get harder — even while your side vision stays clear.

"Wait and see"

The old advice. Monitor, and do nothing, until things get worse.

Three older friends looking through a photo album together, smiling — **Why vision matters**Recognising a face, reading a caption, picking out a photo from years ago — this is what protecting central vision is really about.

How AMD can change what you see: the Amsler grid

Opticians use a simple grid like this to check for early signs of AMD. It's worth learning what to look for at home, too.

Normal vision

Straight, even lines in every direction

Possible signs of AMD

Wavy, broken or blurred lines near the centre

This is an illustrative simulation to help you recognise symptoms, not a diagnostic tool or a treatment result. If lines look wavy, patchy or missing when you look at a real grid or a doorframe, book a macular assessment.

The science

The power of light, three ways

Three precise wavelengths, one goal: feeding energy back into the cells behind your sight.²

590nm 660nm 850nm

590 nm

Vascular support

Increases nitric oxide synthesis and vasodilation, which can improve local oxygenation and nutrient delivery to the retina.²

660 nm

Cellular metabolism

Promotes oxygen binding, stimulates ATP metabolic activity, and helps inhibit inflammation and cell death.³

850 nm

Energy production

Drives electron transfer, stimulating ATP metabolic activity and helping inhibit inflammation and cell death.³

Why it matters

The retina is one of the most mitochondria-rich tissues in the body, and mitochondrial dysfunction is a known driver of vision loss in dry AMD.

The target

Cytochrome c oxidase, a key enzyme in the mitochondrial energy chain, absorbs these specific wavelengths of light.

The effect

Activating this enzyme supports electron transport and ATP production — the cell's primary source of energy.

The evidence

Proven. Not just promised.

Tested over 24 months in the LIGHTSITE III trial — the pivotal study behind Valeda's FDA authorisation.&sup4;

84%of Valeda-treated patients improved or maintained vision at around two years, compared to baseline¹

60%+of Valeda-treated patients gained one line or more of vision at around two years¹

0reports of phototoxicity across three LIGHTSITE clinical trials&sup5;

LIGHTSITE III trial design

98 patients · 145 eyesAged 50+, with a confirmed diagnosis of dry AMD, randomised 2:1 into treatment groups.&sup4;

24 monthsDouble-masked, sham-controlled, randomised, multi-centre trial design.&sup4;

Primary endpoint metMean best-corrected visual acuity change from baseline was assessed at Month 13 and Month 21.&sup4;

Figures reflect n=98 subjects / 145 eyes from the LIGHTSITE III trial (references 1–5, footer). Valeda is not a cure for dry AMD, the evidence base continues to develop, and individual results vary. Suitability is confirmed only after a clinical retinal assessment.

What treatment is designed to target: drusen deposits

Published research on Valeda has reported reduced drusen volume in some treated patients.&sup7; This is an original illustrative diagram of that concept — not an actual scan, and not a guaranteed outcome.

Illustrative · Before

Drusen deposit present

Raised deposit beneath the retinal layers

→

Illustrative · After a course

Reduced drusen deposit

What a positive response may look like

This diagram is a simplified, original illustration created to explain the concept behind Valeda treatment — it is not a real OCT scan, not a photograph, and not a specific patient's result. Individual scans and outcomes vary, and only your optometrist can assess your own retina.&sup7;

Am I suitable?

Could Valeda be right for you?

Suitability is only confirmed after a clinical retinal assessment with Sukhi — this is a general guide, not a diagnosis.

Often suitable

✓You have a diagnosis of early or intermediate dry AMD, with drusen present
✓You are aged 50 or over
✓You have not been diagnosed with wet (neovascular) AMD
✓You want an active option beyond "watch and wait" monitoring

Usually not suitable

×You have wet (neovascular) AMD or central-involving geographic atrophy
×You have a known photosensitivity to yellow, red or near-infrared light
×You have a history of light-triggered conditions such as epilepsy or migraine
×You are pregnant, breastfeeding, or have significant cataracts affecting your vision

A clinician operating the Valeda device while a doctor supervises a patient's session — **Non-invasive, in the chair**No dilation, no injections, no downtime — you sit comfortably while the device delivers each short session.

The Valeda Light Delivery System with a smiling patient — **Just a few minutes**Each session is short and simple — many patients read or chat throughout.

Photography courtesy of Valeda / LumiThera product literature, used to illustrate the treatment — not photographs of Sukhi Eye Spa patients.

Check in on your vision

Is it time for a macular assessment?

Answer six quick questions about your vision. It takes under a minute and isn't a diagnosis — just a helpful starting point.

Your result

Your journey

Simple. Calm. Unhurried.

Consult & assess

Macular assessment

A full retinal assessment with Sukhi to confirm your diagnosis, check for wet AMD, and explain honestly whether Valeda is right for you.

Treatment course

Nine short sessions

Each course is nine sessions over three to five weeks. Sessions take only a few minutes per eye — no dilation, no injections, no downtime.

Maintain & review

Ongoing courses

The published protocol is six courses (54 sessions) across two years, with regular reviews of your vision along the way.

What one full course of treatment looks like

Highlighted squares = your first 9-session course. The full published protocol repeats this six times (54 sessions) over two years.&sup6;

Valeda is offered as a transparent package price, covering your consultation and treatment course, confirmed at your assessment. Ask us about course pricing when you enquire.

Sukhi Cheema, Optometrist at Sukhi Eye Spa

Led by Sukhi Cheema

25 years looking after Leamington Spa's eyes

Sukhi Cheema is an optometrist with 25 years of specialist experience across glaucoma, medical retina and dry eye care, based at Sukhi Eye Spa on Regent Street, Leamington Spa.

25 years of clinical eye care experience
Specialist interest in medical retina and glaucoma
Every Valeda assessment is consultant-led, not delegated
Independent, boutique practice in the heart of Leamington Spa

What patients say

Trusted by Leamington Spa

Questions

Frequently asked questions

What is Valeda and how does it work?

Valeda is a photobiomodulation device that applies three specific wavelengths of light (590nm, 660nm and 850nm) to the retina. These wavelengths are absorbed by mitochondria in retinal cells, supporting the energy production that can decline in dry AMD. It is non-invasive, requires no dilation, injections or anaesthesia, and each session takes only a few minutes.

Does Valeda cure dry AMD?

No. Valeda is not a cure. Clinical trial data shows it can help improve or maintain vision in many patients with early or intermediate dry AMD over the treatment period, but the evidence base is still developing and results vary between individuals. Your suitability is assessed at a retinal consultation.

How many sessions does Valeda involve, and how long do they take?

A course is nine short sessions, usually delivered over three to five weeks. The published treatment protocol involves six courses (54 sessions) spread across two years. Each session takes only a few minutes per eye, with no dilation and no downtime.

Is Valeda safe?

Valeda is FDA-authorised, and no treatment-related phototoxicity was reported across three LIGHTSITE clinical trials. As with any treatment, suitability depends on your individual eye health, which is why every patient is assessed first.

How much does Valeda cost?

Valeda is offered privately as a transparent package price covering your consultation and treatment course. We'll confirm the exact price and any available options at your assessment.

Is Valeda available on the NHS?

No. Valeda is privately provided and not currently funded by the NHS.

Get in touch

Book your Valeda macular assessment

Tell us a little about your vision, and we'll arrange a consultation with Sukhi to see whether Valeda could help.

Call — 01926 893 033
Email — hello@sukhieyes.co.uk
Visit — 64D Regent Street, Leamington Spa, CV32 5EG